Please assess the completion status of the following clinical trial:

Trial Title: Islet Cell Transplantation in Patients With Type I Diabetes With Previous Kidney Transplantation

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients between 18 and 60 years of age.~2. Patients with type 1 diabetes mellitus.~3. Patients with a renal transplant that is more than 6 months old.~4. Patients with stable renal graft function for the preceding 6 months, i.e. no episodes of rejection and changes in serum creatinine no more than 0.5 mg/dl from baseline.~5. Patients who are taking tacrolimus, sirolimus +/- steroids for maintenance immunosuppression for at least 6 months and are tolerating levels satisfactory for islet transplantation without severe complications.~6. Patients with a body mass index (BMI) of less than or equal to 26.~Exclusion Criteria:~1. Stimulated or basal C-peptide \> 0.3 ng/ml.~2. Patients with unstable renal function - serum creatinine greater than 0.5 mg/dl above baseline.~3. Patients with proteinuria (albuminuria \> 300 mg in 24 hours +/- protein) of new onset since kidney transplantation. If proteinuria or albuminuria is thought to originate from the native kidney(s) this will not be an exclusion criterion.~4. Patients with corrected creatinine clearance of less than 40.~5. Patients weighing more than 80 kg.~6. Patients with a body mass index (BMI) of greater than 26.~7. Insulin requirement \> 1.0 U/kg/d.~8. Anemia (hemoglobin: males \< 11.0 g/dl; females \< 10.0 g/dl).~9. Abnormal liver function tests (consistently \> 1.5 x normal range).~10. Unstable diabetic retinopathy.~11. Evidence of acute or chronic active Epstein-Barr virus (EBV) infection (IgM ≥ IgG). Patients will be eligible if serological testing becomes consistent with previous exposure (i.e. IgG \> IgM).~12. Patients with history of malignancy or current malignancy other than non-melanomatous skin cancer, or finding of any lesions or symptoms during screening that are suspicious for malignancy, until properly investigated and ruled out.~13. Patients with elevation of prostate-specific antigen \> 4 unless malignancy has been excluded.~14. Patients with unstable cardiovascular status.~15. Patients with active infections until adequately treated, unless treatment is not judged as necessary by the investigators (including, but not limited to, mild skin and nail fungal infections).~16. Patients with serological evidence of infection with HIV, human t cell lymphotropic virus 1 (HTLV 1), HTLV 2, or hepatitis B (patients with serology consistent with previous vaccination and a history of vaccination are acceptable).~17. Patients with history and/or serological evidence of hepatitis C (those patients with hepatitis C, already transplanted in this protocol will continue in this trial).~18. Positive tuberculin test (unless proof of adequate treatment for latent tuberculosis can be provided).~19. Patients with active peptic ulcer disease, gallstones, hepatic hemangioma, or portal hypertension.~20. Patients who are pregnant or breastfeeding, or who intend to procreate.~21. Patients who are sexually active females who are not:~    * post-menopausal,~   * surgically sterile, or~   * using an acceptable method of contraception (oral contraceptives, Norplant, Depo-Provera, and barrier devices combined with spermicidal gel are acceptable; condoms used alone are not acceptable).~22. Active alcohol or substance abuse; smoking in the last 6 months.~23. Patients with evidence of sensitization, i.e. panel reactive antibody (PRA) testing greater than 20%.~24. Lack of updated immunizations per current Centers for Disease Control (CDC) guidelines, as well as immunization against hepatitis B, pneumococcus, and influenza (during season), unless medically contraindicated.~25. Patients with psychogenic factors, which are judged at psychological evaluation, which make it unsafe to undergo islet transplantation, or which preclude therapeutic compliance.~26. Patients with any condition or any circumstance that would make it unsafe to undergo an islet transplant.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Islet Transplantation (Type: EXPERIMENTAL): Islet Transplantation in subjects with a previous kidney transplant.

Based on this trial design, predict the completion outcome and termination type (if applicable).